The theory that beta-amyloid (Abeta) is the main cause of Alzheimer's has taken yet another bashing after a closely watched trial evaluating Eli Lilly & Co.'s solanezumab and Roche's gantenerumab in people in the early stages of a rare, inherited form of the disease yielded disappointing results.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?